Jazz Pharmaceuticals Director Mark Douglas Smith Files Form 144 to Sell $857K in Common Stock

Form 144 Filing Analysis: Jazz Pharmaceuticals plc (JAZZ)

Overview

On August 31, 2026, Mark Douglas Smith, a Director of Jazz Pharmaceuticals plc, filed a Form 144 notice proposing the sale of 3,507 shares of Common Stock with an estimated aggregate market value of $857,602.00 (approx. $244.54 per share).

Transaction Details

• Filer: Mark Douglas Smith (Director)
• Security: Common Stock
• Shares to be Sold: 3,507
• Aggregate Market Value: $857,602.00
• Broker: E*TRADE Financial Corporation
• Acquisition Nature: Restricted Stock Vesting on August 28, 2026 (3,507 shares acquired as equity compensation)
• Shares Outstanding: 64,914,577

Past 3-Month Activity

• June 15, 2026: Sold 1,157 shares for gross proceeds of $266,746.00.

Significance Assessment

• Significance Level: Low
• Context: The proposed sale represents approximately 0.005% of the company's 64.9M outstanding shares. The shares were acquired via standard director equity compensation (RSU vesting) just days prior on August 28, 2026, indicating routine liquidity management and tax-related diversification rather than a directional signal on company fundamentals.